Parnax Lab Ltd has released its FY 2025-26 annual report ahead of its 44th AGM on September 29, 2026. While standalone revenue and profit declined, the company posted a consolidated profit after tax of Rs 11.80 crore. Shareholders will vote on the appointment of new statutory auditors and material related-party transactions with its subsidiary, Naxpar Pharma.
Parnax Lab Releases FY 2025-26 Annual Report
Consolidated PAT stands at Rs 11.80 crore for FY 2025-26, compared to Rs 11.54 crore in the previous year.
Standalone revenue dipped to Rs 6.63 crore from Rs 7.02 crore in the prior fiscal.
Reader Takeaway: Consolidated profits rose slightly, but standalone operations faced a decline; watch for upcoming related-party transaction approvals.
What just happened
Parnax Lab Ltd has published its Annual Report for the 2025-26 fiscal year. The company has officially scheduled its 44th Annual General Meeting for September 29, 2026. The meeting agenda includes the appointment of M/s. Ladha Singhal & Associates as statutory auditors for a five-year tenure and seeking shareholder approval for material related-party transactions with Naxpar Pharma Private Limited.
Why this matters
The filing highlights a divergence between standalone and consolidated performance. While the standalone business saw a reduction in both revenue (Rs 6.63 crore) and net profit (Rs 0.89 crore) compared to the previous year, the broader consolidated entity recorded a stable profit after tax of Rs 11.80 crore. The approval of related-party transactions, involving sales and purchases up to Rs 5 crore per transaction, is a key governance item for shareholders to monitor.
What changes now
Following the board's decision to not recommend a dividend for the year, investors are focused on the AGM. The appointment of new statutory auditors signals a change in the financial oversight team. Additionally, the pre-approval of material transactions with the subsidiary for the next two financial years provides a framework for the company's internal operations and cash flow management within the Naxpar group ecosystem.
What to track next
Investors should monitor the outcome of the 44th AGM. The management has expressed an intent to grow within the veterinary pharmaceutical market, so tracking progress on this expansion strategy and the impact of the new auditor appointment will be essential for gauging operational efficiency moving forward.